Pharmacoeconomic Analysis of Brentuximab Vedotin Therapy in Relapsed or Refractory Cd30+ Systemic Anaplastic Large Cell Lymphoma in Patients Over 18 Years of Age: Health Budget Impact Analysis
PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology
doi 10.17749/2070-4909.2017.10.1.039-045
Full Text
Open PDFAbstract
Available in full text
Date
January 1, 2017
Authors
Publisher
IRBIS